Navigation Links
FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
Date:9/19/2011

actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends to
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... , April 20, 2015 This report analyzes ... the following Product Segments: Non-Powered Breast Pumps, and Powered Breast ... Canada , Japan , ... and Rest of World. Annual estimates and forecasts are provided ... analysis is provided for these markets. Market data and analytics ...
(Date:4/20/2015)... 20, 2015 This report analyzes the worldwide markets ... Toxicology Testing (In-Vivo, & In-Vitro), and ADME Testing. The report ... , Japan , Europe ... World. Annual estimates and forecasts are provided for the period ... for these markets. Market data and analytics are derived from ...
(Date:4/20/2015)... April 20, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... results for the Phase 1 study of MM-302, ... breast cancer.  The results were presented today by ... oral session at the 2015 American Association for ... Philadelphia, PA. Data described the safety ...
Breaking Medicine Technology:World Breast Pumps Industry 2World Breast Pumps Industry 3World Breast Pumps Industry 4World Breast Pumps Industry 5World Breast Pumps Industry 6World Breast Pumps Industry 7World Breast Pumps Industry 8World Breast Pumps Industry 9World Breast Pumps Industry 10World Breast Pumps Industry 11World Breast Pumps Industry 12World Breast Pumps Industry 13World Breast Pumps Industry 14World ADME-Toxicology Testing Industry 2World ADME-Toxicology Testing Industry 3World ADME-Toxicology Testing Industry 4World ADME-Toxicology Testing Industry 5World ADME-Toxicology Testing Industry 6World ADME-Toxicology Testing Industry 7World ADME-Toxicology Testing Industry 8World ADME-Toxicology Testing Industry 9World ADME-Toxicology Testing Industry 10World ADME-Toxicology Testing Industry 11World ADME-Toxicology Testing Industry 12World ADME-Toxicology Testing Industry 13World ADME-Toxicology Testing Industry 14World ADME-Toxicology Testing Industry 15World ADME-Toxicology Testing Industry 16World ADME-Toxicology Testing Industry 17World ADME-Toxicology Testing Industry 18World ADME-Toxicology Testing Industry 19Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 2Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 3Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 4Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 5
... BioTrends Research Group, Inc. announces the release of the ... and Cimzia report. The survey was completed by ... qualitative interviews with a subset (n=20) of the survey respondents to ... employed to differentiate the products. Over the course of the ...
... , ATLANTA, Dec. 23 Alimera Sciences, Inc., a privately ... commercialization of prescription ophthalmic pharmaceuticals, today reported top-line results from ... The FAME Study consists of two Phase 3 pivotal clinical ... Iluvien in the treatment of diabetic macular edema (DME). The ...
Cached Medicine Technology:Cimzia Draws Even With Simponi at Six Months Post Launch According to Recent BioTrends Survey 2Cimzia Draws Even With Simponi at Six Months Post Launch According to Recent BioTrends Survey 3Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 2Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 3Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 4Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 5Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 6
(Date:4/21/2015)... Nashville, Tenn. – Radsource, a ... Picture Archiving and Communication Systems (PACS), has expanded ... in the first quarter of 2015. , Kentucky ... TN) and Lowcountry Orthopaedics & Sports Medicine (Charleston, ... archiving services. Mt. San Rafael Hospital (Trinidad, CO) ...
(Date:4/21/2015)... 2015 With a growing number of ... Worldwide indicates that international political instability and terrorism top ... survey by Clements, a global insurance provider with 68 ... their country of citizenship, also found strong concern but ... health care insurance overseas . , Asked to choose ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Now, busy Diet ... with the company’s new diet breakfast omelets. Like ... are shipped in dry ice and are delivered directly to ... vegetable or southwestern omelets that not only appeal to the ... reach their ideal weight with healthy, low carbohydrate meals. ...
(Date:4/21/2015)... 2015 The University of Scranton ... Health Informatics to answer the growing demand for ... meaningful, comprehensive wellness profile for better individual, real-world ... development and implementation of health services and systems. ... and managerial operations in the healthcare sector,” says ...
(Date:4/21/2015)... 21, 2015 In early April, Autism ... lights to draw attention to a growing global crisis. ... time is the unique educational needs of individuals on ... wide and diverse and each autistic person is unique ... That is, the educational and emotional needs of individuals ...
Breaking Medicine News(10 mins):Health News:Radsource Adds 4 ProtonPACS Clients in 1st Quarter 2Health News:Potential Expatriate Retirees Fear Political Violence, International Health Insurance Coverage 2Health News:Potential Expatriate Retirees Fear Political Violence, International Health Insurance Coverage 3Health News:Diet Doc Makes Dieting for People on the Go Easier than ever before with Pre-Packaged Diet Meals, Desserts, Snacks and new Breakfast Omelets 2Health News:Diet Doc Makes Dieting for People on the Go Easier than ever before with Pre-Packaged Diet Meals, Desserts, Snacks and new Breakfast Omelets 3Health News:Diet Doc Makes Dieting for People on the Go Easier than ever before with Pre-Packaged Diet Meals, Desserts, Snacks and new Breakfast Omelets 4Health News:The University of Scranton Launches Online MS in Health Informatics 2Health News:The University of Scranton Launches Online MS in Health Informatics 3Health News:In Light of Autism Awareness Month,The Glenholme School Illuminates the Benefits of Therapeutic Boarding School for Students on the Spectrum 2Health News:In Light of Autism Awareness Month,The Glenholme School Illuminates the Benefits of Therapeutic Boarding School for Students on the Spectrum 3Health News:In Light of Autism Awareness Month,The Glenholme School Illuminates the Benefits of Therapeutic Boarding School for Students on the Spectrum 4
... University of California, San Diego, have identified a key ... in humans and mice. This groundbreaking discovery has implications ... of patients with pulmonary arterial hypertension and prevent the ... this debilitating disease. In a paper to be ...
... today,s Scientific Program of the 2009 American Academy of ... Meeting include: John T. Flynn, MD, Columbia University School ... in caring for the vision of the tiniest premature ... Stanford University School of Medicine, on barriers to glaucoma ...
... ... Advantage has developed a proprietary web application named “iCompli®” designed to ... their physician protocols. The application is designed to notify the ... their mobile phone. iCompli® will work with any mobile device or ...
... patients have best chance at some visual recovery, research suggests ... improve the vision of people with a severe form of ... new study shows. , People with LCA, which is caused ... vision loss and abnormal eye movements in early infancy and ...
... ... Debate , ... (Vocus) October 22, 2009 -- According to the Centers for Disease Control and Prevention, the ... country. They also report that hospitalizations of related cases have been above average for this ...
... "Physician ... of EMR Adoption , , ... Doylestown, PA (PRWEB) October 23, 2009 -- myemrchoice.com announced that they will ... Doctors EMR Quarterly and the EMR Power Ranking. The new EMR planning resources ...
Cached Medicine News:Health News:UC San Diego researchers reverse pulmonary arterial hypertension in mouse models 2Health News:Treating ROP in tiny preemies; better glaucoma follow-up in urban clinic 2Health News:Treating ROP in tiny preemies; better glaucoma follow-up in urban clinic 3Health News:Bariatric Advantage Launches First of Its Kind Mobile Vitamin Reminder Web Application 2Health News:Gene Therapy Offers Hope for Severe Hereditary Eye Disease 2Health News:Progressive Radio Network Takes on Controversial H1N1 Vaccine Debate 2Health News:Progressive Radio Network Takes on Controversial H1N1 Vaccine Debate 3Health News:MyEMRchoice.com develops EMR Power Rankings for Selection of Electronic Medical Records 2
... Reference Series 2000 Pipette is a synonym ... compact and robust design, and superior operating ... to operate the measuring stroke and blow-out ... features:Eppendorf "pipette/tip" system ensures utmost accuracy and ...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... Pipetman Ultra is a fully adjustable, ... display. It is the latest member of ... same characteristics: robustness, accuracy, and precision. We ... on feedback from our customers. Eight models ...
Medicine Products: